Kimberly Gentile
Chief Tech/Sci/R&D Officer at BIOHAVEN LTD.
Net worth: 5 M $ as of 30/03/2024
Kimberly Gentile active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - | - |
Portage Pharmaceutical Ltd.
 Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Chief Operating Officer | - | - |
Career history of Kimberly Gentile
Former positions of Kimberly Gentile
| Companies | Position | Start | End |
|---|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | - | 02/10/2022 |
| Corporate Officer/Principal | 31/01/2014 | 02/10/2022 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 31/12/1999 | 31/01/2014 |
| SCIREX Corp. | Corporate Officer/Principal | 31/12/1995 | 31/05/2000 |
Training of Kimberly Gentile
| Salem State University | Undergraduate Degree |
Statistics
International
| United States | 4 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOHAVEN LTD. | Health Technology |
| Private companies | 3 |
|---|---|
| SCIREX Corp. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Commercial Services |
- Stock Market
- Insiders
- Kimberly Gentile
- Experience
